The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis

BACKGROUND: Second-generation androgen receptor inhibitors (ARIs) have been developed and approved for treating castration-resistant prostate cancer (CRPC). There is a lack of direct comparison of the therapeutic effects and adverse events between the conventional ARI (bicalutamide) and three second...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xianlu, Zhang, Gejun, Wang, Jianfeng, Bi, Jianbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950258/
https://www.ncbi.nlm.nih.gov/pubmed/36843606
http://dx.doi.org/10.3389/fendo.2023.1131033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950258/
https://www.ncbi.nlm.nih.gov/pubmed/36843606
http://dx.doi.org/10.3389/fendo.2023.1131033

Ejemplares similares